PT1830847E - Tratamento para o cancro - Google Patents

Tratamento para o cancro Download PDF

Info

Publication number
PT1830847E
PT1830847E PT58133513T PT05813351T PT1830847E PT 1830847 E PT1830847 E PT 1830847E PT 58133513 T PT58133513 T PT 58133513T PT 05813351 T PT05813351 T PT 05813351T PT 1830847 E PT1830847 E PT 1830847E
Authority
PT
Portugal
Prior art keywords
cancer
treatment
Prior art date
Application number
PT58133513T
Other languages
English (en)
Original Assignee
Pitney Pharmaceuticals Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2004906983A external-priority patent/AU2004906983A0/en
Application filed by Pitney Pharmaceuticals Pty Ltd filed Critical Pitney Pharmaceuticals Pty Ltd
Publication of PT1830847E publication Critical patent/PT1830847E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
PT58133513T 2004-12-06 2005-12-06 Tratamento para o cancro PT1830847E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
AU2004906983A AU2004906983A0 (en) 2004-12-06 Treatment for cancer

Publications (1)

Publication Number Publication Date
PT1830847E true PT1830847E (pt) 2015-02-05

Family

ID=36577596

Family Applications (1)

Application Number Title Priority Date Filing Date
PT58133513T PT1830847E (pt) 2004-12-06 2005-12-06 Tratamento para o cancro

Country Status (9)

Country Link
US (2) US20090286838A1 (pt)
EP (1) EP1830847B1 (pt)
JP (1) JP2008522984A (pt)
KR (1) KR101287917B1 (pt)
CN (1) CN101111248A (pt)
CA (1) CA2589828C (pt)
ES (1) ES2528363T3 (pt)
PT (1) PT1830847E (pt)
WO (1) WO2006060853A1 (pt)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009043093A1 (en) * 2007-10-04 2009-04-09 Newsouth Innovations Pty Limited Hif inhibition
KR20090046142A (ko) 2007-11-05 2009-05-11 삼성전자주식회사 입력 필체 자동 변환 시스템 및 방법
EP2251010A1 (en) 2009-05-08 2010-11-17 Sygnis Bioscience GmbH & Co. KG Use of thiabendazole and derivatives thereof for the therapy of neurological conditions
US20120064008A1 (en) * 2009-05-20 2012-03-15 Bruce Zetter Compositions for the treatment of metastatic cancer and methods of use thereof
WO2011041914A1 (en) * 2009-10-09 2011-04-14 University Health Network (Uhn) Use of flubendazole and vinca alkaloids for treatment of hematological diseases
WO2011106273A1 (en) 2010-02-25 2011-09-01 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
EP2880014B1 (en) * 2012-08-06 2017-05-17 Pitney Pharmaceuticals Pty Limited Compounds for the treatment of mtor pathway related diseases
CN103054858A (zh) * 2013-01-21 2013-04-24 杭州雷索药业有限公司 奥苯达唑在制备抗血管生成类药物中的应用
CA2922575C (en) * 2013-11-01 2022-10-11 Newsouth Innovations Pty Limited Pharmaceutical combinations for the treatment of cancer
CN111388469B (zh) * 2019-10-21 2021-11-02 温州医科大学 一种芬苯达唑在制备抗肿瘤药物中的应用
KR102516896B1 (ko) * 2020-10-19 2023-04-03 고려대학교 산학협력단 벤즈이미다졸 유도체 또는 이의 약학적으로 허용가능한 염 및 이의 용도
CN113648308A (zh) * 2021-09-14 2021-11-16 东莞市人民医院 奥芬达唑作为抗卵巢癌药物的应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5900429A (en) 1997-01-28 1999-05-04 The Procter & Gamble Company Method for inhibiting the growth of cancers
PE11499A1 (es) * 1997-05-16 1999-03-01 Procter & Gamble Tratamiento del hiv y cancer
US6506783B1 (en) * 1997-05-16 2003-01-14 The Procter & Gamble Company Cancer treatments and pharmaceutical compositions therefor
GB9900752D0 (en) * 1999-01-15 1999-03-03 Angiogene Pharm Ltd Benzimidazole vascular damaging agents
US6423734B1 (en) * 1999-08-13 2002-07-23 The Procter & Gamble Company Method of preventing cancer
AU2001257325A1 (en) 2000-04-28 2001-11-12 The Procter And Gamble Company Cancer treatment
WO2002067932A1 (en) 2001-01-11 2002-09-06 Board Of Regents, The University Of Texas System Antihelminthic drugs as a treatment for hyperproliferative diseases
US6693125B2 (en) * 2001-01-24 2004-02-17 Combinatorx Incorporated Combinations of drugs (e.g., a benzimidazole and pentamidine) for the treatment of neoplastic disorders
EP1379242B1 (en) * 2001-03-26 2012-08-15 Newsouth Innovations Pty Limited Method for treatment of cancer and compositions for use therein
AU2003302721B2 (en) * 2002-08-02 2009-10-08 Beyondspring Pharmaceuticals, Inc. Dehydrophenylahistins and analogs thereof and the synthesis of dehydrophenylahistins and analogs thereof

Also Published As

Publication number Publication date
KR101287917B1 (ko) 2013-07-23
ES2528363T3 (es) 2015-02-09
EP1830847A4 (en) 2012-09-12
US8835478B2 (en) 2014-09-16
US20090286838A1 (en) 2009-11-19
US20120214856A1 (en) 2012-08-23
CA2589828A1 (en) 2006-06-15
EP1830847B1 (en) 2014-11-19
KR20070112113A (ko) 2007-11-22
WO2006060853A1 (en) 2006-06-15
EP1830847A1 (en) 2007-09-12
JP2008522984A (ja) 2008-07-03
CN101111248A (zh) 2008-01-23
CA2589828C (en) 2014-07-08

Similar Documents

Publication Publication Date Title
EP1814544A4 (en) CANCER TREATMENTS
ZA200805877B (en) Pyridiazinone derivatives for tumour treatment
EP1830847A4 (en) CANCER TREATMENT
EP1755394A4 (en) METHOD OF TREATING CANCER
IL178920A0 (en) Treatment for pancreatic cancer
IL183059A0 (en) Cancer treatment method
IL179323A0 (en) Cancer treatment method
GB2430002B (en) Well treatment
IL179359A0 (en) Cancer treatment method
GB0517387D0 (en) Combinations for the treatment of cancer
GB0428187D0 (en) Cancer treatment
GB0413346D0 (en) Treating cancer
IL187792A0 (en) 4-anilino-3-quinolinecarbonitriles for the treatment of cancer
EP1802617A4 (en) CANCER TREATMENT METHOD
ZA200805522B (en) Dioxoiane dérivates for the treatment of cancer
GB0426141D0 (en) Treatment
GB0424085D0 (en) Well treatment
GB0525535D0 (en) Tumour treatment
GB0507685D0 (en) Cancer treatment
GB0404675D0 (en) Cancer treatment
GB0423273D0 (en) Treatment of cancer
GB0410379D0 (en) Treatment of cancer
GB0517386D0 (en) Combinations for the treatment of cancer
GB0710871D0 (en) Cancer treatment
GB0503566D0 (en) Treatment for cancer